A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022*

Download All
2022 ASCO Annual Meeting, June 3-7, 2022, in Chicago, Illinois, USA; EHA 2022 Congress, June 9-12, 2022, in Vienna, Austria; 2022 Pan Pacific Lymphoma Conference, July 18-22, 2022, in Koloa, Hawaii, USA; ESMO 2022 Annual Congress, September 9-13, 2022, in Paris, France; 2022 SOHO Annual Meeting, September 28 - October 1, 2022, in Houston, Texas, USA
Get up to date on emerging data with BTK inhibitors for chronic lymphocytic leukemia and mantle cell lymphoma presented at the 2022 meetings of ASCO, EHA, Pan Pacific Lymphoma, ESMO, and SOHO with on-demand webcasts, expert podcasts, downloadable slides, commentaries, and a “year in review” module.
Othman Al-Sawaf, MD
Matthew S. Davids, MD, MMSc
Toby Eyre, MBChB, MD
Anthony Mato, MD, MSCE
Jeff Sharman, MD

On-Demand Webcasts

In this on-demand webcast from a live symposium, experts Othman Al-Sawaf, MD, and Toby Eyre, MBChB, MD, discuss current and emerging data on BTK inhibitor therapy for the treatment of patients with CLL and MCL.

Othman Al-Sawaf, MD Toby Eyre, MBChB, MD Released: October 21, 2022

Watch this on-demand webcast capturing a dynamic workshop in which 3 experts discuss best practices and future directions in the use of BTK inhibitors for chronic lymphocytic leukemia and mantle cell lymphoma.

Matthew S. Davids, MD, MMSc Anthony Mato, MD, MSCE Jeff Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: November 22, 2022 Expired: No longer available for credit
Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings